8-K: Myriad Genetics Q2 2026 Results Show Revenue Decline, Focus on Efficiency

Myriad Genetics reported a 11% year-over-year revenue decrease for Q2 2026, driven by lower average revenue per test and volume challenges in certain segments, while launching new initiatives for efficiency and scalability.

Summary

• Myriad Genetics announced second quarter 2026 revenue of $190.7 million, an 11% decrease compared to the prior year, attributed to a 1% volume decline and a 9% drop in average revenue per test.
• The company experienced volume growth in its Cancer Care Continuum business (up 6% year-over-year) but saw declines in Prenatal Health (down 9% year-over-year).
• Operating expenses for Q2 2026 were $165.9 million, a significant decrease from $481.0 million in Q2 2025, which included substantial impairment charges.
• Adjusted operating expenses increased by $6.7 million year-over-year to $150.5 million, reflecting investments in strategic areas.
• The company reported an operating loss of $38.9 million for the second quarter of 2026.
• Cash and cash equivalents stood at $115.2 million as of June 30, 2026.
• Myriad Genetics has revised its full-year 2026 financial guidance, projecting revenue between $770 million and $790 million.
• New initiatives, including a strategic review and an efficiency program named 'Ascend' supported by a professional services firm, are underway to drive growth and profitability.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant revenue decline, operating loss, and downward revision of financial guidance, despite some positive developments in specific business segments.

Positives

• Cancer Care Continuum business showed 6% year-over-year test volume growth in the second quarter.
• Launched Prolaris + AI for prostate cancer and expanded Precise MRD to include colorectal and renal cancers.
• Submitted Precise MRD for breast cancer to MolDX for coverage determination.
• Maintained strong laboratory operating performance with productivity and cost-per-test improvements supporting gross margins.
• Hereditary Cancer and Mental Health tests showed solid demand, though offset by other segment challenges.
• Gross margin was 66.6% in Q2 2026, with adjusted gross margin guidance for the full year set at 66%-67%.

Negatives

• Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year.
• Average revenue per test decreased 9% year-over-year, partly due to an $11.0 million reduction from changes in estimates of cash collections.
• Prenatal Health test volumes declined 9% year-over-year.
• Operating loss of $38.9 million in the second quarter of 2026.
• Cash flow used in operations was $8.3 million in Q2 2026, and adjusted operating cash outflow was $7.7 million.
• Adjusted free cash flow was $(10.9) million in Q2 2026.
• Revised full-year 2026 revenue guidance downwards to $770 $790 million.

Risks

• Increased payer friction impacting average revenue per test for hereditary cancer testing.
• Volume challenges in Prenatal Health.
• Potential for continued pressure on average revenue per test.
• Risks associated with the successful implementation of new efficiency and scalability initiatives.
• Uncertainty regarding the optimal allocation of capital and enhancement of shareholder value following a product portfolio evaluation.
• The company's ability to achieve revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable.
• Changes in governmental or private insurers coverage and reimbursement levels for the company's tests.

Future Outlook

Myriad Genetics has revised its full-year 2026 revenue guidance to a range of $770 million to $790 million, reflecting second quarter results and updated assumptions for business trends. Adjusted Gross Margin is expected to be between 66% and 67%. The company is suspending its previous full-year 2026 Adjusted EBITDA guidance.

Management Comments

• "In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume growth supported by the ramp up of our expanded sales team, the launch of Prolaris + AI, the expansion of Precise MRD to include colorectal cancer (CRC) and renal cancers, along with the submission of Precise MRD breast to MolDX."
• "During the quarter, we advanced work on a strategic review with the intention to identify initiatives to increase growth, profitability, and liquidity. We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm."
• "We are also doing a rigorous evaluation of our product portfolio to determine the optimal allocation of capital and enhancement of shareholder value."
• "Myriad Genetics' second quarter 2026 performance fell short of our expectations, as solid demand for our Hereditary Cancer and Mental Health tests was offset by volume challenges in Prenatal Health and increased payer friction."
• "Mitigating average revenue per test pressure for hereditary cancer testing from this increased payer friction is a top priority, and we are executing a comprehensive action plan."
• "While we are revising our full-year 2026 financial guidance due to lower Prenatal Health test volumes and more conservative assumptions regarding average revenue per test, we remain optimistic about our 2027 financial profile as we execute on multiple initiatives."

Industry Context

StockSavvy.ai notes that Myriad Genetics' Q2 2026 results reflect broader industry pressures in molecular diagnostics, including increased payer scrutiny and the need for greater efficiency. The company's focus on cancer care, particularly with new AI-enabled and MRD tests, aligns with industry trends towards more personalized and precise oncology treatments. However, the revenue decline and revised guidance highlight the competitive and reimbursement challenges within the sector.

Comparison to Industry Standards

• The 11% year-over-year revenue decline is a significant underperformance compared to the growth rates typically seen in the molecular diagnostics sector, which has often experienced double-digit growth.
• The 9% decrease in average revenue per test is concerning and suggests pricing or reimbursement pressures that may be more acute than for some competitors, though specific industry benchmarks for this metric are highly product-dependent.
• The 6% volume growth in the Cancer Care Continuum is a positive indicator, but it is offset by declines in other segments, indicating a mixed performance across product lines, unlike companies with more diversified or consistently growing portfolios.

Stakeholder Impact

• Shareholders: Potential negative impact due to revenue decline, operating loss, and revised financial guidance, which may affect stock price.
• Employees: Potential impact from efficiency initiatives, though specific details are not provided.
• Payers: Increased engagement and execution of revenue cycle initiatives to improve reimbursement predictability.
• Customers (Healthcare Providers/Patients): Continued focus on product development and clinical utility in cancer care and prenatal health.

Next Steps

• Continue executing revenue cycle initiatives to improve reimbursement predictability.
• Drive productivity and cost-per-test improvements.
• Implement initiatives from the 'Ascend' program to increase efficiency, effectiveness, and scalability.
• Conduct a rigorous evaluation of the product portfolio to optimize capital allocation.
• Continue enrollment in the CONNECTOR study for the FirstGene Multiple Prenatal Screen.
• Await coverage determination for Precise MRD for breast cancer from MolDX.

Key Dates

Recommendation

The company is facing significant headwinds with declining revenues and profitability, necessitating a strategic review and efficiency drive. While there are positive developments in the Cancer Care Continuum, the overall financial performance and revised guidance warrant a cautious approach. A 'hold' recommendation reflects the uncertainty surrounding the effectiveness of new initiatives and the challenging market conditions, balanced against the company's established position in molecular diagnostics.

Keywords

molecular diagnostic testing, precision medicine, cancer care, prostate cancer, prostate cancer test, prostate cancer screening, prostate cancer diagnosis, prostate cancer treatment